Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer

Haruki Kaku, Tomoyasu Tsushima, Yasutomo Nasu, Takashi Saika, Ryoji Arata, Yoshinori Shirasaki, Kyohei Kurose, Tetsuya Nakata, Hiromi Kumon, Teruhisa Ohashi, Yoshiyuki Miyaji

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To date, there has been no effective therapy against hormone-refractory prostate cancer (HRPC). This led us to evaluate the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and Cis-platin (CDDP) combination chemotherapy in patients with HRPC. ECT at a daily dose of 560mg was given intravenously in combination with IFM, 1.2 g/m2, on days 1 to 5, and CDDP, 70 mg/ m2, on day 1. This combination therapy was given every 3 to 4 weeks. Twenty-one patients with HRPC were enrolled in this trial. An objective response of more than 50% reduction in prostate -specific antigen was observed in nine out of eighteen patients (50%), and more than 50% reduction in bidimensionally measurable soft-tissue lesions was observed in two out of seven patients (29%). The median response duration of overall partial response cases was 40 weeks, while the median response duration of overall partial response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable; nausea/vomiting (67%), alopecia (48%), anemia (76%), leukocytopenia (57%), thrombocytopenia (48%), renal dysfunction (24%) and liver dysfunction (19%) were noticed. Severe toxicity was observed in two cases, one case with myocardial infarction and one case with deep vein thrombosis. We conclude that the ECT, IFM and CDDP combination chemotherapy regimen can be highly recommended for the treatment of HRPC.

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalNishinihon Journal of Urology
Volume64
Issue number4
Publication statusPublished - 2002

Fingerprint

Estramustine
Ifosfamide
Combination Drug Therapy
Prostatic Neoplasms
Phosphates
Hormones
Alopecia
Leukopenia
Prostate-Specific Antigen
Venous Thrombosis
Thrombocytopenia
Nausea
Vomiting
Liver Diseases
Anemia
Therapeutics
Myocardial Infarction
Kidney
Survival

Keywords

  • Cis-platin
  • Estramustine phosphate
  • Hormone-refractory prostate cancer
  • Ifosfamide

ASJC Scopus subject areas

  • Urology

Cite this

Kaku, H., Tsushima, T., Nasu, Y., Saika, T., Arata, R., Shirasaki, Y., ... Miyaji, Y. (2002). Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer. Nishinihon Journal of Urology, 64(4), 236-241.

Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer. / Kaku, Haruki; Tsushima, Tomoyasu; Nasu, Yasutomo; Saika, Takashi; Arata, Ryoji; Shirasaki, Yoshinori; Kurose, Kyohei; Nakata, Tetsuya; Kumon, Hiromi; Ohashi, Teruhisa; Miyaji, Yoshiyuki.

In: Nishinihon Journal of Urology, Vol. 64, No. 4, 2002, p. 236-241.

Research output: Contribution to journalArticle

Kaku, H, Tsushima, T, Nasu, Y, Saika, T, Arata, R, Shirasaki, Y, Kurose, K, Nakata, T, Kumon, H, Ohashi, T & Miyaji, Y 2002, 'Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer', Nishinihon Journal of Urology, vol. 64, no. 4, pp. 236-241.
Kaku, Haruki ; Tsushima, Tomoyasu ; Nasu, Yasutomo ; Saika, Takashi ; Arata, Ryoji ; Shirasaki, Yoshinori ; Kurose, Kyohei ; Nakata, Tetsuya ; Kumon, Hiromi ; Ohashi, Teruhisa ; Miyaji, Yoshiyuki. / Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer. In: Nishinihon Journal of Urology. 2002 ; Vol. 64, No. 4. pp. 236-241.
@article{d29cf9bd62e5435f8522df6416bca3d6,
title = "Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer",
abstract = "To date, there has been no effective therapy against hormone-refractory prostate cancer (HRPC). This led us to evaluate the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and Cis-platin (CDDP) combination chemotherapy in patients with HRPC. ECT at a daily dose of 560mg was given intravenously in combination with IFM, 1.2 g/m2, on days 1 to 5, and CDDP, 70 mg/ m2, on day 1. This combination therapy was given every 3 to 4 weeks. Twenty-one patients with HRPC were enrolled in this trial. An objective response of more than 50{\%} reduction in prostate -specific antigen was observed in nine out of eighteen patients (50{\%}), and more than 50{\%} reduction in bidimensionally measurable soft-tissue lesions was observed in two out of seven patients (29{\%}). The median response duration of overall partial response cases was 40 weeks, while the median response duration of overall partial response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable; nausea/vomiting (67{\%}), alopecia (48{\%}), anemia (76{\%}), leukocytopenia (57{\%}), thrombocytopenia (48{\%}), renal dysfunction (24{\%}) and liver dysfunction (19{\%}) were noticed. Severe toxicity was observed in two cases, one case with myocardial infarction and one case with deep vein thrombosis. We conclude that the ECT, IFM and CDDP combination chemotherapy regimen can be highly recommended for the treatment of HRPC.",
keywords = "Cis-platin, Estramustine phosphate, Hormone-refractory prostate cancer, Ifosfamide",
author = "Haruki Kaku and Tomoyasu Tsushima and Yasutomo Nasu and Takashi Saika and Ryoji Arata and Yoshinori Shirasaki and Kyohei Kurose and Tetsuya Nakata and Hiromi Kumon and Teruhisa Ohashi and Yoshiyuki Miyaji",
year = "2002",
language = "English",
volume = "64",
pages = "236--241",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "4",

}

TY - JOUR

T1 - Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer

AU - Kaku, Haruki

AU - Tsushima, Tomoyasu

AU - Nasu, Yasutomo

AU - Saika, Takashi

AU - Arata, Ryoji

AU - Shirasaki, Yoshinori

AU - Kurose, Kyohei

AU - Nakata, Tetsuya

AU - Kumon, Hiromi

AU - Ohashi, Teruhisa

AU - Miyaji, Yoshiyuki

PY - 2002

Y1 - 2002

N2 - To date, there has been no effective therapy against hormone-refractory prostate cancer (HRPC). This led us to evaluate the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and Cis-platin (CDDP) combination chemotherapy in patients with HRPC. ECT at a daily dose of 560mg was given intravenously in combination with IFM, 1.2 g/m2, on days 1 to 5, and CDDP, 70 mg/ m2, on day 1. This combination therapy was given every 3 to 4 weeks. Twenty-one patients with HRPC were enrolled in this trial. An objective response of more than 50% reduction in prostate -specific antigen was observed in nine out of eighteen patients (50%), and more than 50% reduction in bidimensionally measurable soft-tissue lesions was observed in two out of seven patients (29%). The median response duration of overall partial response cases was 40 weeks, while the median response duration of overall partial response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable; nausea/vomiting (67%), alopecia (48%), anemia (76%), leukocytopenia (57%), thrombocytopenia (48%), renal dysfunction (24%) and liver dysfunction (19%) were noticed. Severe toxicity was observed in two cases, one case with myocardial infarction and one case with deep vein thrombosis. We conclude that the ECT, IFM and CDDP combination chemotherapy regimen can be highly recommended for the treatment of HRPC.

AB - To date, there has been no effective therapy against hormone-refractory prostate cancer (HRPC). This led us to evaluate the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and Cis-platin (CDDP) combination chemotherapy in patients with HRPC. ECT at a daily dose of 560mg was given intravenously in combination with IFM, 1.2 g/m2, on days 1 to 5, and CDDP, 70 mg/ m2, on day 1. This combination therapy was given every 3 to 4 weeks. Twenty-one patients with HRPC were enrolled in this trial. An objective response of more than 50% reduction in prostate -specific antigen was observed in nine out of eighteen patients (50%), and more than 50% reduction in bidimensionally measurable soft-tissue lesions was observed in two out of seven patients (29%). The median response duration of overall partial response cases was 40 weeks, while the median response duration of overall partial response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable; nausea/vomiting (67%), alopecia (48%), anemia (76%), leukocytopenia (57%), thrombocytopenia (48%), renal dysfunction (24%) and liver dysfunction (19%) were noticed. Severe toxicity was observed in two cases, one case with myocardial infarction and one case with deep vein thrombosis. We conclude that the ECT, IFM and CDDP combination chemotherapy regimen can be highly recommended for the treatment of HRPC.

KW - Cis-platin

KW - Estramustine phosphate

KW - Hormone-refractory prostate cancer

KW - Ifosfamide

UR - http://www.scopus.com/inward/record.url?scp=0036247383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036247383&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036247383

VL - 64

SP - 236

EP - 241

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 4

ER -